Previous 10 | Next 10 |
2023-05-12 13:48:39 ET Shares of Harrow Health (NASDAQ: HROW) were down more than 24% as of 1:45 p.m. ET Friday after the company reported first-quarter earnings following the close of trading Thursday. The pharmaceutical company focuses on eye therapies. The company's stock is ...
2023-05-12 13:14:08 ET Gainers: GSI Technology ( GSIT ) +149% . ARS Pharmaceuticals ( SPRY ) +80% . Zapp Electric Vehicles Group Limited ( ZAPP ) +42% . AirSculpt Technologies ( AIRS ) +39% . Blue Bird Corporation ( BLBD ) +34% ....
2023-05-11 21:43:09 ET Harrow Health, Inc. (HROW) Q1 2023 Earnings Conference Call May 11, 2023, 4:45 PM ET Company Participants Jamie Webb - Director, Communications and IR Mark Baum - Chief Executive Officer Andrew Boll - Chief Financial Officer Conferenc...
2023-05-11 16:04:20 ET Harrow Health press release ( NASDAQ: HROW ): Q1 Non-GAAP EPS of -$0.03. Revenue of $26.1M (+18.0% Y/Y) beats by $1.11M . For further details see: Harrow Health Non-GAAP EPS of -$0.03, revenue of $26.1M beats by $1.11M
First Quarter 2023 and Recent Selected Highlights: Record revenues of $26.1 million, up 18% over $22.1 million for the prior-year quarter and 28% over sequential quarter revenues of $20.3 million. Completed transfer of New Drug Applications (NDAs) for ILEVRO®, NEVANAC®, and MA...
Harrow Health, Inc. (NASDAQ: HROW) is the focus of IBN's latest stock spotlight. The company's shares have moved 0.51% on the day to $27.44. Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical co...
Harrow (NASDAQ: HROW), a leading U.S. eyecare pharmaceutical company, today announced the launch of FDA-approved IHEEZO ™ at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting being held May 5‑8, 2023, in San Diego, California. The Harrow commerc...
Harrow (NASDAQ: HROW), a leading U.S. eyecare pharmaceutical company, today announced the completion of the transfer to Harrow of the New Drug Applications (NDAs) for ILEVRO® (nepafenac ophthalmic suspension) 0.3%, NEVANAC® (nepafenac ophthalmic suspension) 0.1%, and MAXIDEX® (dexa...
Harrow Health, Inc. (NASDAQ: HROW) is the focus of IBN's latest stock spotlight. The company's shares have moved 2.73% on the day to $25.92. Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical co...
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the first quarter ended March 31, 2023, on Thursday, May 11, 2023, after the market close. The Company will also post its first quarter Letter to Stockholders to th...
News, Short Squeeze, Breakout and More Instantly...
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that its management team would attend the 2024 American Society of Retina Specialists (ASRS) Annual Meeting, taking place in Stockholm, Sweden, from July 17-20, 2024. The ASRS Annual Meeting brings tog...
Contract Enhances Purchasing Power for 340B Prime Vendor Program (PVP) Participants; Aligns with Harrow’s Mission to Make Its Products Accessible and Affordable Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that as of July 1, 2024, ...